Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BDC-1001 |
| Trade Name | |
| Synonyms | BDC 1001|BDC1001 |
| Drug Descriptions |
BDC-1001 is an antibody conjugate comprising an ERBB2 (HER2)-targeting antibody linked to a TLR 7/8 agonist, which may enhance antitumor immune response (J Clin Oncol 41, 2023 (suppl 16; abstr 2538)). |
| DrugClasses | HER2 (ERBB2) Antibody 79 |
| CAS Registry Number | NA |
| NCIT ID | C172388 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BDC-1001 | BDC-1001 | 0 | 2 |
| BDC-1001 + Nivolumab | BDC-1001 Nivolumab | 0 | 0 |
| BDC-1001 + Pembrolizumab | BDC-1001 Pembrolizumab | 0 | 1 |
| BDC-1001 + Pertuzumab | BDC-1001 Pertuzumab | 0 | 1 |